her disease and based on a recently published small case series. The success of rituximab was evident by the cessation of further corneal thinning and ability to cease systemic steroids over the last 12 months.
Background: Idiopathic inflammatory myopathies can be classified by clinicopathological phenotype into four major groups: overlap myositis (OM), dermatomyositis (DM), immune mediated necrotising myositis (IMMNM) and inclusion body myositis (IBM). The different phenotypes associate with distinct MSA specificities although a variable percentage within each group are seronegative and the majority of IBM patients are seronegative.
Methods: In NZ, testing for MSA is restricted to two laboratories: Waikato Hospital (WHL) and Canterbury Health Laboratories (CHL). For the period between 3 November 2015 and 2 November 2016, each laboratory information system (LIS) was interrogated for requests for MSA. For the purposes of this report, positive results were grouped into the specificities associated with each of the defined clinicopathological phenotypes.
DM: Mi2, Tif-γ, MDA5, NXP2, SAE1 OM: Ku, PM-Scl-100, PL75, Jo1, PL-7, PL-12, EJ, OJ
IMMNM: HMGCR, SRP
Results: Of screened sera (n = 762, CHL = 610, WHL = 152) 8% were positive for MSA (66/762).
Of those 62 sera, MSA were distributed amongst three clinicopathologically associated autoantibody profiles: DM 27% OM 36%,IMMNM 37%. The most common serum specificities were HMGCR (n = 23, 37%) and Jo-1 (n = 8, 13%). No serum with a specificity to SRP or OJ was detected. 21/23 sera positive for anti-HMGCR had an elevated CPK concentration with the majority >2500 U/L.
Conclusion:
In New Zealand 8% of sera referred for MSA testing were positive and the most common antigen specificity found was to HMGCR. Our analysis indicate that IMMNM make up more than a third of all myositis and may be the most common type of myositis now in NZ. Background: Minimum biodrug concentrations of ≈7 mg/L are predictive of disease remission although there is no consensus on therapeutic drug levels. Very low biodrug concentrations associate with loss of benefit in may be due to ADA. Canterbury Health Laboratories, New Zealand (CHL) has developed a competitive binding ELISA to detect neutralising antibodies whereas most commercial assays utilise a bridging methodology.
P89 HIGH FREQUENCY OF ANTI-DRUG ANTIBODIES (ADA) DETECTED IN SERUM SAMPLES WITH LOW/ABSENT BIODRUG CONCENTRATIONS TAKEN FROM PATIENTS UNDERTAKING TREATMENT WITH ANTI-TNF AGENTS
Methods: Serum samples with low/absent drug concentration defined as <1 mg/L of Infliximab/Adalimumab were tested for ADA using three different methods; the competitive-binding ELISA, the IgG4 ELISA and bridging ELISA. Detection target of the three assays were the reduction of IgG Fc of the drug bound to TNF, bivalent IgG Fab of the ADA and IgG4 Fc of the ADA respectively.
Results: 15.2% (76/497) of referred samples had low/absent concentrations <1 mg/L (adalimumab n = 33 or infliximab n = 43). The competitive binding assay detected ADAs in 44.3% (35/76), bridging assay 35.5% (27/76) and IgG4 ELISA 52.6% (40/76). The bridging ELISA was the least sensitive with all the positive results picked up by the competitive ELISA. The IgG4 ELISA detected an additional 14/76 not picked up by the competitive ELISA. These 14 samples may contain monovalent IgG4 that does not crosslink ADA affecting the performance of our competitive assay. Overall ADAs were detected in 64.5% (49/76) of samples with low/-absent drug concentrations.
Conclusion:
The clinical utility of ADA is assay dependent. The commercial bridging assay is the least sensitive of the three methods used and underestimates the frequency of ADA in serum samples of patients undertaking treatment anti-TNF agents with low/absent drug concentrations (<1 mg/L). With the use of the competitive assay and IgG4 ELISA, the detection of ADA would almost double that of bridging assay alone in our patient cohort. Four patients (three CSU and one idiopathic angioedema) in whom stress was a recognised trigger, were consented and recruited into a brief whole person treatment approach (WPTA) based in non-dualistic concepts of mind and body connectedness, for up to 10 × 1 h long sessions. A mixed methods Grounded Theory and Interpretive Phenomenology Analysis of data derived from these patients were used to explore patients' experience of Mind-Body connection in CSU.
P90 EXPERIENCE IN USE OF A NON-DUALISTIC WHOLE PERSON APPROACH TO PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA
Treatment efficacy rating, using Urticaria Activity Score and the Urticaria Severity Score, and drug usage, showed patients experienced long term resolution of urticarial up to 2 years, and came off regular antihistamine medication. Patients developed chronic urticarial or angioedema in the context of a uniquely meaningful extra-ordinary life experience which overwhelmed the persons personal and relational ability to process it. During the WPTA patients reflected on the meaning of symptoms, process the experience and changed their 'way of being in relation to themselves and others', and their symptoms resolved or improved. Selected CSU patients can be successfully treated using a non-dualistic WPTA. Both qualitative and quantitative data will be presented. A larger study comparing the outcome, cost effectiveness and quality of life of WPTA versus standard treatment alone is warranted. 
P91 NOVEL TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS

